Menu

The Brain-Microbiome Axis: Links Between Neurological Disease and Microbiota

The Scientist will be exploring the connection between the human microbiome and the human brain.

Jun 2, 2018
The Scientist Creative Services Team

The Brain-Microbiome Axis: Links Between Neurological Disease and Microbiota from thescientistllc on Vimeo.

The human microbiome consists of trillions of commensal microbes. These include bacteria, fungi, and viruses, which naturally reside within the human body and have been documented to affect epigenetic mechanisms, metabolic activity, and immune system function. Researchers are now focusing on how microbiome perturbations impact human health and disease. In particular, certain gut microbiota profiles have been strongly linked to the development of neurological disorders, including autism spectrum disorder, schizophrenia, stress, and depression. For a more detailed look at how our resident microbes impact our brains, as well as how microbiome manipulation may open potential therapeutic avenues for these disorders, The Scientist is bringing together a panel of experts who will share their research, summarize the state of the science, and discuss the next steps for those looking to adopt the technique. Attendees will have the opportunity to interact with experts, ask questions, and seek advice on topics related to their research.

Topics to be covered:

  • How resident microbiota can influence the neurological health of their host
  • Whether microbiome composition can alter the course of human neurological disease

Meet the Speakers:

Jane Foster, PhD
Associate Professor
Department of Psychiatry & Behavioral Neurosciences
McMaster University

 

Helen Tremlett, PhD
Professor
Canada Research Chair in Neuroepidemiology and Multiple Sclerosis
Djavad Mowafaghian Centre for Brain Health
Faculty of Medicine (Neurology)
University of British Columbia Hospital

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.